BridgeBio Pharma (BBIO) Amortization of Deferred Charges (2020 - 2026)

BridgeBio Pharma (BBIO) has 5 years of Amortization of Deferred Charges data on file, last reported at $1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges rose 83.0% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $5.3 million (up 6.99% YoY), and the FY2025 full-year result was $4.9 million, down 34.32% from the prior year.
• Amortization of Deferred Charges retreated to $1.8 million in Q1 2026, from $2.0 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $2.1 million in Q4 2024 to a low of $490000.0 in Q3 2025.
• A 3-year average of $1.3 million and a median of $1.4 million in 2025 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges slipped 5.13% in 2025 and surged 83.0% in 2026, its largest moves.
• Tracing BBIO's Amortization of Deferred Charges over 3 years: stood at $2.1 million in 2024, then declined by 5.13% to $2.0 million in 2025, then decreased by 7.15% to $1.8 million in 2026.
• Business Quant data shows BBIO's Amortization of Deferred Charges at $1.8 million in Q1 2026, $2.0 million in Q4 2025, and $490000.0 in Q3 2025.